Objectives: Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related death among women worldwide. Breast cancer bone metastasis is associated with skeletal events, including acute fractures, compression of the spinal cord, surgery and radiotherapy to the spine, as well as bone pain and hypercalcemia, resulting in decreased mobility and diminished quality of life. Greater understanding of the bone metastasis pathophysiology will highly likely to lead to the discovery of an effective treatment option. This study aims to test whether the serum bone profile and expression level of cathepsin K (CTSK) in breast carcinoma is associated with metastasis. Methods: In this study, 116 participants, 58 patients who had been diagnosed with breast cancer (n=22 without metastasis and n=36 with metastasis) and 58 healthy controls were included. Serum biochemical profile and immunostaining of CTSK in the breast carcinoma were investigated. Results: The mean values of calcium, 25-OH Vitamin D, ALP, albumin, phosphorus, magnesium, TSH, cholesterol, PTH and CRP (mg/L) were 11.5±2.03, 28.12±10.5, 93.3±7.9, 3.9±0.3, 3.7±1.64, 1.8±0.24, 2.5±1.5, 165.1±28.02, 63.4±18.9 and 7.7±4.9. Individual data revealed that 70% of patients without metastasis has PTH above normal while 65% has calcium and 62% patients has ALP above normal levels, which were further increased in metastasis. Low Mg levels were detected in 13/58 of the patients with breast cancer and 3/58 of the control group.13/58 of the patients with breast cancer showed low total calcium, and 32/58 of the breast cancer group showed high calcium levels. Conclusion: The present study results suggest that CTSK expressions are associated with a higher tumour stage and distant metastasis, suggesting serum bone profile and level of CTSK expression are significant parameters in the disease diagnosis and monitoring of breast cancer metastasis.
1. Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007;31(5):1031–40.
2. Rangarajan B, Shet T, Wadasadawala T, Nair NS, Sairam RM, Hingmire SS, et al. Breast cancer: An overview of published Indian data. South Asian J Cancer 2016;5(3):86–92.
3. Doddala SM, Suryadevara A, Chinta SK, Madisetty AL. Incidence and pattern of bone metastases at presentation in Indian carcinoma breast patients. Indian J Cancer 2016;53(3):360–2.
4. Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118(3):277–9.
5. Pedica F, Pecori S, Vergine M, Brunelli M, Montagna L, Pedron S, et al. Cathepsin-k as a diagnostic marker in the identification of micro-granulomas in Crohn's disease. Pathologica 2009;101(3):109–11.
6. Le Gall C, Bonnelye E, Clézardin P. Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2008;2(3):218–22.
7. Zheng G, Martignoni G, Antonescu C, Montgomery E, Eberhart C, Netto G, et al. A broad survey of cathepsin K immunoreactivity in human neoplasms. Am J Clin Pathol 2013;139(2):151–9.
8. Duong LT, Wesolowski GA, Leung P, Oballa R, Pickarski M. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis. Mol Cancer Ther 2014;13(12):2898–909.
9. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003;18(2):222–30.
10. Bitu CC, Kauppila JH, Bufalino A, Nurmenniemi S, Teppo S, Keinänen M, et al. Cathepsin K is present in invasive oral tongue squamous cell carcinoma in vivo and in vitro. PLoS One 2013;8(8):e70925.
11. Herroon MK, Rajagurubandara E, Rudy DL, Chalasani A, Hardaway AL, Podgorski I. Macrophage cathepsin K promotes prostate tumor progression in bone. Oncogene 2013;32(12):1580–93.
12. Yamashita K, Iwatake M, Okamoto K, Yamada SI, Umeda M, Tsukuba T. Cathepsin K modulates invasion, migration and adhesion of oral squamous cell carcinomas in vitro. Oral Dis 2017;23(4):518–25.
13. Hlaing TT, Compston JE. Biochemical markers of bone turnover - uses and limitations. Ann Clin Biochem 2014;51(Pt 2):189–202.
14. Wiwanitkit V. High serum alkaline phosphatase levels, a study in 181 Thai adult hospitalized patients. BMC Fam Pract 2001;2:2.
15. Heys SD, Smith IC, Eremin O. Hypercalcaemia in patients with cancer: aetiology and treatment. Eur J Surg Oncol 1998;24(2):139–42.
16. Ijaz A, Mehmood T, Qureshi AH, Anwar M, Dilawar M, Hussain I, Khan FA, Khan DA, Hussain S, Khan IA. Estimation of ionized calcium, total calcium and albumin corrected calcium for the diagnosis of hypercalcemia of malignancy. J Coll Physicians Surg Pak. 2006;16(1):49–52.
17. Francini G, Petrioli R, Maioli E, Gonnelli S, Marsili S, Aquino A, Bruni S. Hypercalcemia in breast cancer. Clin Exp Metastasis. 1993;11(5):359–367.
18. Friedman LS, Martin P, Munoz SJ. Liver Function tests and the objective evaluation of the patient with liver disease. In: Zakim D, Boyer T D, editors. Hepatology: a Textbook of liver diseases. Philadelphia: WB Saunders; 1996. p. 791–833.
19. Fishman WH, Inglis NI, Stolbach LL, Krant MJ. A serum alkaline phosphatase isoenzyme of human neoplastic cell origin. Cancer Res 1968;28(1):150–4
20. Uemura H, Irahara M, Yoneda N, Yasui T, Genjida K, Miyamoto KI, et al. Close correlation between estrogen treatment and renal phosphate reabsorption capacity. J Clin Endocrinol Metab 2000;85(3):1215–9.
21. Mulholland HG, Murray LJ, Anderson LA, Cantwell MM; FINBAR study group. Vitamin D, calcium and dairy intake, and risk of oesophageal adenocarcinoma and its precursor conditions. Br J Nutr 2011;106(5):732–41.
22. Atoe KJ, Idemudia O, Eboreime O. Serum Magnesium Levels in Women with Breast Cancer in Benin City, Nigeria. Int J Tropical Disease Health 2014;4(6):723–8
23. Sartori S, Nielsen I, Tassinari D, Mazzotta D, Vecchiatti G, Sero A, et al. Serum and erythrocyte magnesium concentrations in solid tumours: relationship with stage of malignancy. Magnes Res 1992;5(3):189–92.
24. Favaro E, Amadori A, Indraccolo S. Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy. APMIS 2008;116(7-8):648–59.
25. Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G, Berrino F. Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomarkers Prev 2008;17(7):1719–22.
26. Guo L, Liu S, Zhang S, Chen Q, Zhang M, Quan P, et al. C-reactive protein and risk of breast cancer: A systematic review and meta-analysis. Sci Rep 2015;5:10508.
27. Durlach J, Bara M, Guiet-Bara A, Collery P. Relationship between magnesium, cancer and carcinogenic or anticancer metals. Anticancer Res 1986;6(6):1353–61.
28. Arinola OG, Charles-Davies MA. Micronutrient levels in the plasma of Nigerian females with breast cancer. Afri J Biotech 2008;7(11):1620–1623.
29. Abdelgawad IA, El-Mously RH, Saber MM, Mansour OA, Shouman SA. Significance of serum levels of vitamin D and some related minerals in breast cancer patients. Int J Clin Exp Pathol 2015;8(4):4074–82.
30. Blaszczyk U, Duda-Chodak A. Magnesium: its role in nutrition and carcinogenesis. Rocz Panstw Zakl Hig 2013;64(3):165–71.
31. Castiglioni S, Maier JA. Magnesium and cancer: a dangerous liason. Magnes Res 2011;24(3):S92–100.
32. Wolf FI, Maier JA, Nasulewicz A, Feillet-Coudray C, Simonacci M, Mazur A, et al. Magnesium and neoplasia: from carcinogenesis to tumor growth and progression or treatment. Arch Biochem Biophys 2007;458(1):24–32.
33. Tao MH, Dai Q, Millen AE, Nie J, Edge SB, Trevisan M, et al. Associations of intakes of magnesium and calcium and survival among women with breast cancer: results from Western New York Exposures and Breast Cancer (WEB) Study. Am J Cancer Res 2015;6(1):105–13.
34. Yang CY, Chiu HF, Cheng MF, Hsu TY, Cheng MF, Wu TN. Calcium and magnesium in drinking water and the risk of death from breast cancer. J Toxicol Environ Health A 2000;60(4):231–41.
35. Edwards MH, Parsons C, Bruyère O, Petit Dop F, Chapurlat R, Roemer FW, et al; SEKOIA Study Group. High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study. J Rheumatol 2016;43(3):657–65.
36. Ramaswamy G, Rao VR, Krishnamoorthy L, Ramesh G, Gomathy R, Renukadevi D. Serum levels of bone alkaline phosphatase in breast and prostate cancers with bone metastasis. Indian J Clin Biochem 2000;15(2):110–3.
37. Damodar G, Smitha T, Gopinath S, Vijayakumar S, Rao Y. An evaluation of hepatotoxicity in breast cancer patients receiving injection Doxorubicin. Ann Med Health Sci Res 2014;4(1):74–9.
38. Owiredu WK, Donkor S, Addai BW, Amidu N. Serum lipid profile of breast cancer patients. Pak J Biol Sci 2009;12(4):332–8.
39. Kaur RP, Rubal, Dhiman M, Vashitstha R, Munshi A. Serum Albumin Levels in Breast Cancer: Correlation with Overall Survival. J Food Nutr Disord 2017;6(5).
40. Boonpipattanapong T, Chewatanakornkul S. Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J Clin Gastroenterol 2006;40(7):592–5.
41. Win T, Sharples L, Groves AM, Ritchie AJ, Wells FC, Laroche CM. Predicting survival in potentially curable lung cancer patients. Lung 2008;186(2):97–102.
42. Neal CP, Mann CD, Sutton CD, Garcea G, Ong SL, Steward WP, et al. Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur J Cancer 2009;45(1):56–64.
43. Al Dleemy WKA. Effect of Some Antioxidant Parameters in Breast Cancer. Tikrit Journal of Pure Science 2009;14(2):46–50.
44. Pavithra V, Sathisha TG, Kasturi K, Mallika DS, Amos SJ, Ragunatha S. Serum levels of metal ions in female patients with breast cancer. J Clin Diagn Res 2015;9(1):25–7.
45. Fujii T, Ishikawa M, Kubo A, Tanaka Y. Effect of SI-591, a new class of cathepsin K inhibitor with peptidomimetic structure, on bone metabolism in vitro and in vivo. Bone 2015;81:427–34.
46. Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, Yao J, et al. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res 2008;14(17):5357–67.